No quarterly revenue total was found in ANIXA BIOSCIENCES, INC.'s SEC filings.
Anixa Biosciences, Inc. (ANIX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jul 31, 2026 it held $13.9 million in cash and investments and $174,000 in total debt.
Revenue
—
Net income
$-2.61M
-15.4% vs year-ago quarter
Operating cash flow
$-1.77M
-17.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.08
-14.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
34.76M
+5.6% vs year-ago quarter
Net cash
$13.69M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANIX (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- DE
- Headquarters
- San Jose, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 715446
- Former names
- ITUS Corp (until Sep 27, 2018); COPYTELE INC (until Aug 27, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jul 31, 2026 |
Q2 FY2026 Apr 30, 2026 |
Q1 FY2026 Jan 31, 2026 |
Q4 FY2025 Oct 31, 2025 |
Q3 FY2025 Jul 31, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.7M | -$2.6M | -$2.7M | -$2.9M | -$2.4M |
| Net income | -$2.6M | -$2.5M | -$2.6M | -$2.7M | -$2.3M |
| Diluted EPS | -$0.08 | -$0.07 | -$0.08 | $0.03 | -$0.07 |
| Operating cash flow | -$1.8M | -$1.7M | -$2.6M | -$1.3M | -$1.5M |
| Total assets | $15.1M | $14.9M | $15.2M | $16.1M | $17.7M |
| Total liabilities | $1.9M | $1.6M | $1.4M | $2.1M | $2.2M |
| Stockholders' equity | $14.5M | $14.5M | $15.1M | $15.2M | $16.6M |
| Cash and investments | $13.9M | $13.7M | $14.2M | $15.2M | $16.0M |
| Total debt | $174,000 | $184,000 | $193,000 | $204,000 | $213,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 9, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | Jun 10, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Mar 11, 2026 | Mar 10, 2026 |
| 10-Q | Quarterly report | Mar 9, 2026 | Jan 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 9, 2026 | Feb 9, 2026 |
| 10-K | Annual report | Jan 12, 2026 | Oct 31, 2025 |
All 983 Anixa Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.